{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:54Z","timestamp":1793414154094,"version":"4.5.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Nusinersen is the first drug approved for spinal muscular atrophy (SMA) treatment. In this study, we aimed to evaluate the long-term safety and efficacy of nusinersen, assess the therapeutic effects based on the treatment initiation timing and baseline motor function, and explore the perception of functional improvement from either parents or patients, utilizing 3-year nationwide follow-up data in South Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled patients with SMA who were treated with nusinersen under the National Health Insurance coverage, with complete motor score records available and a minimum treatment duration of 6 months. To evaluate the motor function of patients, the Hammersmith Infant Neurological Examination-2 (HINE-2) was used for type 1 and the Expanded Hammersmith Functional Motor Scale (HFMSE) was used for types 2 and 3 patients. A significant improvement was defined as a HINE-2 score gain \u22655 for patients with type 1 and an HFMSE score <jats:bold>\u2265<\/jats:bold> 3 for patients with types 2 and 3 SMA. Effects of treatment timing were assessed. Patients with type 2 were further categorized based on baseline motor scores for outcome analysis. We also analyzed a second dataset from five tertiary hospitals with the information on parents\/patients-reported impressions of improvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study comprised 137 patients, with 21, 103, and 13 patients representing type 1, 2, and 3 SMA, respectively. At the 3-year follow-up, the analysis encompassed 7 patients with type 1, 12 patients with type 2, and none with type 3. Nearly half of all enrolled patients across SMA types (42.8, 59.2 and 46.2%, respectively) reached the 2-year follow-up for analysis. Patients with type 1 SMA exhibited gradual motor function improvement over 1-, 2-, and 3-year follow-ups (16, 9, and 7 patients, respectively). Patients with type 2 SMA demonstrated improvement over 1-, 2-, and 3-year follow-ups (96, 61 and 12 patients, respectively). Early treatment from symptom onset resulted in better outcomes for patients with type 1 and 2 SMA. In the second dataset, 90.7% of 108 patients reported subjective improvement at the 1-year follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Nusinersen treatment for types 1\u20133 SMA is safe and effective in long-term follow-up. Early treatment initiation was a significant factor affecting long-term motor outcome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1294028","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T08:15:50Z","timestamp":1703060150000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: findings from a three-year nationwide study in Korea"],"prefix":"10.3389","volume":"14","author":[{"given":"Jaeso","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Sun","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hye","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Guk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Mock","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hee","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 Sma patients treated with Nusinersen: a critical review and Meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00207454.2022.2095270","article-title":"Real-world safety and effectiveness of Nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance","author":"Tachibana","year":"2022","journal-title":"Int J Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/jnnp-2020-324532","article-title":"Nusinersen in spinal muscular atrophy type 1 from neonates to Young adult: 1-year data from three Asia-Pacific regions","volume":"92","author":"Chan","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Observational Cohort Study"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type ii spinal muscular atrophy pediatric patients treated with Nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of Nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of Nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Commun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of Nusinersen after one year of treatment in 123 children with Sma type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/mus.25705","article-title":"Motor milestone assessment of infants with spinal muscular atrophy using the Hammersmith infant neurological exam\u2014part 2: experience from a Nusinersen clinical study","volume":"57","author":"Bishop","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.apmr.2013.04.001","article-title":"Motor function measure: validation of a short form for Young children with neuromuscular diseases","volume":"94","author":"de Lattre","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 Sma infants, children and Young adults: preliminary results on motor function","volume":"28","author":"Pane","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"E1312","DOI":"10.1212\/Wnl.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 a cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acn3.51514","article-title":"Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy","volume":"9","author":"Pane","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn screening for spinal muscular atrophy in New York state: clinical outcomes from the first 3 years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","article-title":"Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study","volume":"7","author":"Kariyawasam","year":"2023","journal-title":"The Lancet Child & Adolescent Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3233\/JND-221510","article-title":"Newborn screening for Sma - can a wait-and-see strategy be responsibly justified in patients with four Smn2 copies?","volume":"9","author":"Blaschek","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","article-title":"Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy","volume":"27","author":"Stolte","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4","volume":"25","author":"Wadman","year":"2018","journal-title":"Eur J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.nmd.2014.01.003","article-title":"Hammersmith functional motor scale and motor function Measure-20 in non ambulant Sma patients","volume":"24","author":"Mazzone","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of Nusinersen in longstanding adult 5q-Sma type 3\u2013a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"Journal of neuromuscular diseases"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejpn.2022.07.005","article-title":"Survival in patients diagnosed with Sma at less than 24 months of age in a population-based setting before, during and after introduction of Nusinersen therapy. Experience from Sweden","volume":"40","author":"Berglund","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with Nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.nmd.2006.08.011","article-title":"Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy","volume":"16","author":"Arkblad","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of Nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with Nusinersen: 4-year follow-up of motor, respiratory and bulbar function","author":"Pane","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dmcn.15171","article-title":"Evolution of bulbar function in spinal muscular atrophy type 1 treated with Nusinersen","volume":"64","author":"Weststrate","year":"2022","journal-title":"Dev Med Child Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13023-020-01498-2","article-title":"Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the cure Sma community update survey","volume":"15","author":"Belter","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2329048X211008725","DOI":"10.1177\/2329048X211008725","article-title":"Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment","volume":"8","author":"Pierzchlewicz","year":"2021","journal-title":"Child Neurol Open"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The Alsfrs-R: a revised Als functional rating scale that incorporates assessments of respiratory function","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"669509","DOI":"10.3389\/fmed.2021.669509","article-title":"Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the us, Eu, and China using a logic model","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/pds.4962","article-title":"Use of real-world evidence in regulatory decisions for rare diseases in the United States-current status and future directions","volume":"29","author":"Wu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost effectiveness of Nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019","journal-title":"PharmacoEconomics"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1843277","DOI":"10.1080\/20016689.2020.1843277","article-title":"Economic burden of spinal muscular atrophy: an analysis of claims data","volume":"8","author":"Belter","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"750742","DOI":"10.3389\/fphar.2021.750742","article-title":"Assessing the value of Nusinersen for spinal muscular atrophy: a comparative analysis of reimbursement submission and appraisal in European countries","volume":"12","author":"Blonda","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1294028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T08:15:53Z","timestamp":1703060153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1294028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":41,"alternative-id":["10.3389\/fneur.2023.1294028"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1294028","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"article-number":"1294028"}}